Targeting USP9X-AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma.

ABSTRACT:

Background & aims

Hepatocellular carcinoma (HCC) is a highly heterogeneous solid tumor with high morbidity and mortality. AT-rich interaction domain 1A (ARID1A) accounts for up to 10% of mutations in liver cancer, however, its role in HCC remains controversial, and no targeted therapy has been established.

Methods

The expression of ARID1A in clinical samples was examined by Western blot and immunohistochemical staining. ARID1A was knocked out by Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) in HCC cell lines, and the effects of glucose deprivation on cell viability, proliferation, and apoptosis were measured. Mass spectrometry analysis was used to find ARID1A-interacting proteins, and the result was verified by co-immun

SUBMITTER: Zhang FK 

PROVIDER: S-EPMC9117818 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature